Does gut microbiota dysbiosis impact the metabolic alterations of hydrogen sulfide and lanthionine in patients with chronic kidney disease?


Journal

BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981

Informations de publication

Date de publication:
26 Oct 2024
Historique:
received: 24 02 2024
accepted: 18 10 2024
medline: 27 10 2024
pubmed: 27 10 2024
entrez: 27 10 2024
Statut: epublish

Résumé

Chronic Kidney Disease (CKD) is characterized by a methionine-related metabolic disorder involving reduced plasma levels of hydrogen sulfide (H The gut microbiota of 88 CKD patients (non-dialysis, hemodialysis, and transplant patients) and 26 healthy controls were profiled using 16 S-amplicon sequencing. H The CKD population exhibited a tenfold increase in serum lanthionine associated with kidney dysfunction. Despite lanthionine retention, hemodialysis and transplant patients had significantly lower serum H The metabolic deregulation of H

Sections du résumé

BACKGROUND BACKGROUND
Chronic Kidney Disease (CKD) is characterized by a methionine-related metabolic disorder involving reduced plasma levels of hydrogen sulfide (H
METHODS METHODS
The gut microbiota of 88 CKD patients (non-dialysis, hemodialysis, and transplant patients) and 26 healthy controls were profiled using 16 S-amplicon sequencing. H
RESULTS RESULTS
The CKD population exhibited a tenfold increase in serum lanthionine associated with kidney dysfunction. Despite lanthionine retention, hemodialysis and transplant patients had significantly lower serum H
CONCLUSIONS CONCLUSIONS
The metabolic deregulation of H

Identifiants

pubmed: 39462312
doi: 10.1186/s12866-024-03590-0
pii: 10.1186/s12866-024-03590-0
doi:

Substances chimiques

Hydrogen Sulfide YY9FVM7NSN
lanthionine JO78O46X3K
Sulfides 0
Alanine OF5P57N2ZX

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

436

Subventions

Organisme : European Union's Horizon 2020 research and innovation program
ID : Grant agreement No [860329]
Organisme : European Union's Horizon 2020 research and innovation program
ID : Grant agreement No [860329]
Organisme : European Union's Horizon 2020 research and innovation program
ID : Grant agreement No [860329]

Informations de copyright

© 2024. The Author(s).

Références

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7.
doi: 10.1016/j.kisu.2021.11.003
Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int. 2009;76:S12–9.
doi: 10.1038/ki.2009.402
Nigam SK, Bush KT. Uremic syndrome of chronic kidney disease: altered remote sensing and signaling. Nat Rev Nephrol. 2019;15:301.
doi: 10.1038/s41581-019-0111-1 pubmed: 30728454 pmcid: 6619437
Perna AF, Ingrosso D. Low hydrogen sulphide and chronic kidney disease: a dangerous liaison. Nephrol Dial Transpl. 2012;27:486–93.
doi: 10.1093/ndt/gfr737
Kuang Q, Xue N, Chen J, Shen Z, Cui X, Fang Y, et al. Low plasma hydrogen sulfide is Associated with impaired renal function and Cardiac Dysfunction. Am J Nephrol. 2018;47:361–71.
doi: 10.1159/000489606 pubmed: 29779029
Perna AF, Di Nunzio A, Amoresano A, Pane F, Fontanarosa C, Pucci P, et al. Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients. Biochimie. 2016;126:97–107.
doi: 10.1016/j.biochi.2016.04.018 pubmed: 27129884
Perna AF, Zacchia M, Trepiccione F, Ingrosso D. The sulfur metabolite lanthionine: evidence for a role as a novel Uremic Toxin. Toxins. 2017;9.
Perna AF, Anishchenko E, Vigorito C, Zacchia M, Trepiccione F, D’Aniello S, et al. Zebrafish, a novel model system to study uremic toxins: the case for the sulfur amino acid lanthionine. Int J Mol Sci. 2018;19:1–16.
doi: 10.3390/ijms19051323
Coppola A, Vigorito C, Lombari P, Martínez YG, Borriello M, Trepiccione F, et al. Uremic Toxin Lanthionine induces endothelial cell mineralization in Vitro. Biomed. 2022;10:444.
Perna AF, Luciano MG, Ingrosso D, Pulzella P, Sepe I, Lanza D, et al. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant off Publ Eur Dial Transpl Assoc -. Eur Ren Assoc. 2009;24:3756–63.
doi: 10.1093/ndt/gfp378
Aminzadeh MA, Vaziri ND. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant off Publ Eur Dial Transpl Assoc -. Eur Ren Assoc. 2012;27:498–504.
doi: 10.1093/ndt/gfr560
Shen X, Carlström M, Borniquel S, Jädert C, Kevil CG, Lundberg JO. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med. 2013;60:195–200.
doi: 10.1016/j.freeradbiomed.2013.02.024 pubmed: 23466556 pmcid: 4077044
Flannigan KL, Mccoy KD, Wallace JL. Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol. 2011;301:188–93.
doi: 10.1152/ajpgi.00105.2011
Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012;3 NOV:448.
Wolf PG, Cowley ES, Breister A, Matatov S, Lucio L, Polak P et al. Diversity and distribution of sulfur metabolic genes in the human gut microbiome and their association with colorectal cancer. Microbiome. 2022;10.
McAuliffe O, Ross RP, Hill C. Lantibiotics: structure, biosynthesis and mode of action. FEMS Microbiol Rev. 2001;25:285–308.
doi: 10.1111/j.1574-6976.2001.tb00579.x pubmed: 11348686
Willey JM, Van Der Donk WA. Lantibiotics: peptides of diverse structure and function. Annu Rev Microbiol. 2007;61:477–501.
doi: 10.1146/annurev.micro.61.080706.093501 pubmed: 17506681
Vasstrand EN, Hofstad T, Endresen C, Jensen HB. Demonstration of lanthionine as a natural constituent of the peptidoglycan of Fusobacterium nucleatum. Infect Immun. 1979;25:775.
doi: 10.1128/iai.25.3.775-780.1979 pubmed: 500186 pmcid: 414514
Vasstrand EN, Jensen HB, Miron T, Hofstad T. Composition of peptidoglycans in Bacteroidaceae: determination and distribution of lanthionine. Infect Immun. 1982;36:114.
doi: 10.1128/iai.36.1.114-122.1982 pubmed: 7076290 pmcid: 351192
Sampaio-Maia B, Simões-Silva L, Pestana M, Araujo R, Soares-Silva IJ. The role of the gut microbiome on chronic kidney disease. Adv Appl Microbiol. 2016;96:65–94.
doi: 10.1016/bs.aambs.2016.06.002 pubmed: 27565581
Jiang S, Xie S, Lv D, Zhang Y, Deng J, Zeng L, et al. A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie Van Leeuwenhoek Int J Gen Mol Microbiol. 2016;109:1389–96.
doi: 10.1007/s10482-016-0737-y
Li FX, Wang MH, Wang JP, Li RS, Zhang YQ. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease. Front Cell Infect Microbiol. 2019;9:206.
doi: 10.3389/fcimb.2019.00206 pubmed: 31245306 pmcid: 6581668
Lun H, Yang W, Zhao S, Jiang M, Xu M, Liu F, et al. Altered gut microbiota and microbial biomarkers associated with chronic kidney disease. MicrobiologyOpen. 2019;8:1–10.
doi: 10.1002/mbo3.678
Hu X, Ouyang S, Xie Y, Gong Z, Du J. Characterizing the gut microbiota in patients with chronic kidney disease. Postgrad Med. 2020;132:495–505.
doi: 10.1080/00325481.2020.1744335 pubmed: 32241215
Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020;69:2131–42.
doi: 10.1136/gutjnl-2019-319766 pubmed: 32241904
Perna AF, Pane F, Sepe N, Fontanarosa C, Pinto G, Zacchia M, et al. Lanthionine and other relevant Sulfur amino acid metabolites: detection of prospective uremic toxins in serum by multiple reaction monitoring Tandem Mass Spectrometry. Methods Mol Biol Clifton NJ. 2019;2007:9–17.
doi: 10.1007/978-1-4939-9528-8_2
Strocchi A, Furne JK, Levitt MD. A modification of the methylene blue method to measure bacterial sulfide production in feces. J Microbiol Methods. 1992;15:75–82.
doi: 10.1016/0167-7012(92)90071-B
Gryp T, Glorieux G, Joossens M, Vaneechoutte M. Comparison of five assays for DNA extraction from bacterial cells in human faecal samples. J Appl Microbiol. 2020;129:378–88.
doi: 10.1111/jam.14608 pubmed: 32034968 pmcid: 7384110
Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–4.
doi: 10.1126/science.aad3503 pubmed: 27126039
Vandeputte D, Kathagen G, D’Hoe K, Vieira-Silva S, Valles-Colomer M, Sabino J et al. Quantitative microbiome profiling links gut community variation to microbial load. Nat. 2017 5517681 2017;551:507–11.
Pedregosa FABIANPEDREGOSAF, Michel V, Grisel OLIVIERGRISELO, Blondel M, Prettenhofer P, Weiss R, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011;12:2825–30.
Jari Oksanen GL, Simpson F, Guillaume Blanchet R, Kindt P, Legendre PR, Minchin et al. vegan: Community Ecology Package. R package version 2.6-4. 2022 n.d.
Iebba V, Zanotta N, Campisciano G, Zerbato V, Di Bella S, Cason C et al. Profiling of oral microbiota and cytokines in COVID-19 patients. Front Microbiol. 2021;12.
Blondel VD, Guillaume JL, Lambiotte R, Lefebvre E. Fast unfolding of communities in large networks. J Stat Mech Theory Exp. 2008;2008:P10008.
doi: 10.1088/1742-5468/2008/10/P10008
Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38:685–8.
doi: 10.1038/s41587-020-0548-6 pubmed: 32483366 pmcid: 7365738
Perna AF, Russo L, D’esposito V, Formisano P, Bruzzese D, Vigorito C et al. Lanthionine, a Novel Uremic Toxin, in the vascular calcification of chronic kidney disease: the role of Proinflammatory cytokines. Int J Mol Sci. 2021;22.
Vigorito C, Anishchenko E, Mele L, Capolongo G, Trepiccione F, Zacchia M et al. Uremic Toxin Lanthionine interferes with the Transsulfuration Pathway, Angiogenetic Signaling and increases intracellular calcium. Int J Mol Sci. 2019;20.
García-Martínez Y, Borriello M, Capolongo G, Ingrosso D, Perna AF. The gut microbiota in kidney transplantation: a target for personalized therapy? Biol. 2023;12:163.
doi: 10.3390/biology12020163
Swarte JC, Douwes RM, Hu S, Vila AV, Eisenga MF, van Londen M et al. Characteristics and dysbiosis of the gut microbiome in renal transplant recipients. J Clin Med. 2020;9.
Souai N, Zidi O, Mosbah A, Kosai I, Manaa JE, Mokhtar NB, et al. Impact of the post-transplant period and Lifestyle diseases on human gut microbiota in kidney graft recipients. Microorganisms. 2020;8:1–19.
doi: 10.3390/microorganisms8111724
Koshida T, Gohda T, Sugimoto T, Asahara T, Asao R, Ohsawa I, et al. Gut Microbiome and Microbiome-Derived metabolites in patients with end-stage kidney disease. Int J Mol Sci. 2023;24:11456.
doi: 10.3390/ijms241411456 pubmed: 37511232 pmcid: 10380578
Wang H, Ainiwaer A, Song Y, Qin L, Peng A, Bao H, et al. Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity. Microbiome. 2023;11:1–16.
Ghoshal U, Shukla R, Srivastava D, Ghoshal UC. Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is Associated with higher methane production. Gut Liver. 2016;10:932–8.
doi: 10.5009/gnl15588 pubmed: 27458176 pmcid: 5087933
Ikee R, Yano K, Tsuru T. Constipation in chronic kidney disease: it is time to reconsider. Ren Replace Ther. 2019;5:51.
doi: 10.1186/s41100-019-0246-3
Crost EH, Coletto E, Bell A, Juge N. Ruminococcus gnavus: friend or foe for human health. FEMS Microbiol Rev. 2023;47:1–23.
doi: 10.1093/femsre/fuad014
Walsh CJ, Guinane CM, O’Toole PW, Cotter PD. A Profile Hidden Markov Model to investigate the distribution and frequency of LanB-encoding lantibiotic modification genes in the human oral and gut microbiome. PeerJ. 2017;5.
Dischinger J, Basi Chipalu S, Bierbaum G, Lantibiotics. Promising candidates for future applications in health care. Int J Med Microbiol. 2014;304:51–62.
doi: 10.1016/j.ijmm.2013.09.003 pubmed: 24210177

Auteurs

Yuselys Garcia-Martinez (Y)

Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy. yuselys.garciamartinez@unicampania.it.

Elena Alexandrova (E)

Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy.

Valerio Iebba (V)

Gustave Roussy Cancer Campus, ClinicObiome, Villejuif, Paris, France.

Carlo Ferravante (C)

Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy.

Michelle Spinelli (M)

Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.

Gianluigi Franci (G)

Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy.

Angela Amoresano (A)

Department of Chemical Sciences, University of Napoli Federico II, Naples, Italy.

Alessandro Weisz (A)

Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, Italy.
Genome Research Center for Health - CRGS, Campus of Medicine, University of Salerno, Baronissi, Italy.

Francesco Trepiccione (F)

Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.

Margherita Borriello (M)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Diego Ingrosso (D)

Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Alessandra F Perna (AF)

Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH